Kazakhstan set to register first cancer drug by end-2025
ASTANA, Kazakhstan (MNTV) — Kazakhstan plans to register its first domestically developed cancer treatment drug by the end of 2025, Minister of Science and Higher Education Sayasat Nurbek announced at a recent government briefing.
According to Nurbek, the drug passed first-stage clinical trials in 2024, initially targeting colorectal cancer but now expanded to patients with other cancer types.
“Clinical trials are currently underway across different cancer types. Patients are showing promising results, with an average tumor reduction of 30%. Some have even achieved remission. Our goal is to complete the trials and register the drug by late 2025,” Kursiv Media quoted Nurbek as saying.
“By the end of this year, we will compile all trial data, analyze the results, and present the drug officially at a press conference,” Nurbek noted.
In November 2024, Kursiv Media reported on a joint effort by researchers from the National Laboratory Astana and the Kazakh Institute of Oncology and Radiology in Almaty to determine the maximum tolerated dose of DVC, the new cancer drug. Patients selected for the study received up to 36 injections in increasing doses, based on strict criteria.
If approved, this could mark a significant step for Kazakhstan’s domestic pharmaceutical research and cancer treatment capabilities.
Have Your Say!
Have you been affected by the issues raised in this story? Please share your experiences by emailing haveyoursay@soundvision.com.
Please include a contact number if you are willing to speak to a Muslim Network TV’s representative. You can also get in touch in the following ways:
Tweet: @MuslimNetworkTV
We must take charge of our narrative. Research indicates that 92% of their Muslim coverage is negative. Help us change that.
